Works by Richardson, Paul G.

Results: 215
    1
    2
    3
    4
    5
    6

    Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?

    Published in:
    Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 547, doi. 10.1007/s10557-021-07207-w
    By:
    • Castro, Pedro;
    • Palomo, Marta;
    • Moreno-Castaño, Ana Belen;
    • Fernández, Sara;
    • Torramadé-Moix, Sergi;
    • Pascual, Georgina;
    • Martinez-Sanchez, Julia;
    • Richardson, Edward;
    • Téllez, Adrián;
    • Nicolas, Josep M.;
    • Carreras, Enric;
    • Richardson, Paul G.;
    • Badimon, Juan José;
    • Escolar, Gines;
    • Diaz-Ricart, Maribel
    Publication type:
    Article
    7
    8

    New Drugs for Myeloma.

    Published in:
    Oncologist, 2007, v. 12, n. 6, p. 664, doi. 10.1634/theoncologist.12-6-664
    By:
    • Richardson, Paul G.;
    • Mitsiades, Constantine;
    • Schlossman, Robert;
    • Munshi, Nikhil;
    • Anderson, Kenneth
    Publication type:
    Article
    9

    Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00695-5
    By:
    • Kumar, Shaji;
    • Baizer, Lawrence;
    • Callander, Natalie S.;
    • Giralt, Sergio A.;
    • Hillengass, Jens;
    • Freidlin, Boris;
    • Hoering, Antje;
    • Richardson, Paul G.;
    • Schwartz, Elena I.;
    • Reiman, Anthony;
    • Lentzsch, Suzanne;
    • McCarthy, Philip L.;
    • Jagannath, Sundar;
    • Yee, Andrew J.;
    • Little, Richard F.;
    • Raje, Noopur S.
    Publication type:
    Article
    10

    Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

    Published in:
    2022
    By:
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.;
    • Rodriguez, Cesar;
    • Jakubowiak, Andrzej;
    • Efebera, Yvonne;
    • Reeves, Brandi;
    • Wildes, Tanya;
    • Holstein, Sarah A.;
    • Anderson Jr, Larry D.;
    • Badros, Ashraf;
    • Shune, Leyla;
    • Chari, Ajai;
    • Pei, Huiling;
    • Cortoos, Annelore;
    • Patel, Sharmila;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Richardson, Paul G.;
    • Voorhees, Peter
    Publication type:
    Letter
    11
    12
    13

    Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
    By:
    • Richardson, Paul G.;
    • Lee, Hans C.;
    • Abdallah, Al-Ola;
    • Cohen, Adam D.;
    • Kapoor, Prashant;
    • Voorhees, Peter M.;
    • Hoos, Axel;
    • Wang, Karrie;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Richmond, Scott;
    • Jewell, Roxanne C.;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Lonial, Sagar
    Publication type:
    Article
    14
    15
    16
    17
    18
    19

    The power of proteasome inhibition in multiple myeloma.

    Published in:
    Expert Review of Proteomics, 2018, v. 15, n. 12, p. 1033, doi. 10.1080/14789450.2018.1543595
    By:
    • Guerrero-Garcia, Thomas A.;
    • Gandolfi, Sara;
    • Laubach, Jacob P.;
    • Hideshima, Teru;
    • Chauhan, Dharminder;
    • Mitsiades, Constantine;
    • Anderson, Kenneth C.;
    • Richardson, Paul G.
    Publication type:
    Article
    20
    21
    22

    Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 8, p. 985, doi. 10.1002/ajh.25134
    By:
    • Leleu, Xavier;
    • Masszi, Tamas;
    • Bahlis, Nizar J.;
    • Viterbo, Luisa;
    • Baker, Bartrum;
    • Gimsing, Peter;
    • Maisnar, Vladimir;
    • Samoilova, Olga;
    • Rosiñol, Laura;
    • Langer, Christian;
    • Song, Kevin;
    • Izumi, Tohru;
    • Cleeland, Charles;
    • Berg, Deborah;
    • Lin, Huamao Mark;
    • Zhu, Yanyan;
    • Skacel, Tomas;
    • Moreau, Philippe;
    • Richardson, Paul G.
    Publication type:
    Article
    23
    24
    25
    26
    27

    Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

    Published in:
    American Journal of Hematology, 2010, v. 85, n. 9, p. 670, doi. 10.1002/ajh.21788
    By:
    • Ghobrial, Irene M.;
    • Xie, Wanling;
    • Padmanabhan, Swaminathan;
    • Badros, Ashraf;
    • Rourke, Meghan;
    • Leduc, Renee;
    • Chuma, Stacey;
    • Kunsman, Janet;
    • Warren, Diane;
    • Poon, Tiffany;
    • Harris, Brianna;
    • Sam, Amy;
    • Anderson, Kenneth C.;
    • Richardson, Paul G.;
    • Treon, Steven P.;
    • Weller, Edie;
    • Matous, Jeffrey
    Publication type:
    Article
    28

    Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01272-2
    By:
    • Cirstea, Diana;
    • Shome, Rajib;
    • Samur, Mehmet;
    • Talluri, Srikanth;
    • Connolly, Joseph J.;
    • Wright, Alexandra Jean;
    • Duvallet, Emilie;
    • Joyce, Amanda N. R.;
    • Lively, Kathleen;
    • Basinsky, Gina;
    • Yee, Andrew J.;
    • Chase, Cristiana Costa;
    • Malek, Ehsan;
    • Niesvizky, Ruben;
    • Richardson, Paul G.;
    • Raje, Noopur S.
    Publication type:
    Article
    29

    Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01149-w
    By:
    • Richardson, Paul G.;
    • Perrot, Aurore;
    • Mikhael, Joseph;
    • Martin, Thomas;
    • Beksac, Meral;
    • Spicka, Ivan;
    • Capra, Marcelo;
    • D'Agostino, Mattia;
    • Sonneveld, Pieter;
    • Bisht, Kamlesh;
    • Fukao, Taro;
    • Zhang, Rick;
    • Tada, Keisuke;
    • Tekle, Christina;
    • Macé, Sandrine;
    • Klippel, Zandra;
    • van de Velde, Helgi;
    • Moreau, Philippe
    Publication type:
    Article
    30
    31
    32

    Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-024-55308-5
    By:
    • Nadeem, Omar;
    • Aranha, Michelle P.;
    • Redd, Robert;
    • Timonian, Michael;
    • Magidson, Sophie;
    • Lightbody, Elizabeth D.;
    • Alberge, Jean-Baptiste;
    • Bertamini, Luca;
    • Dutta, Ankit K.;
    • El-Khoury, Habib;
    • Bustoros, Mark;
    • Laubach, Jacob P.;
    • Bianchi, Giada;
    • O'Donnell, Elizabeth;
    • Wu, Ting;
    • Tsuji, Junko;
    • Anderson, Kenneth C.;
    • Getz, Gad;
    • Trippa, Lorenzo;
    • Richardson, Paul G.
    Publication type:
    Article
    33

    Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 687, doi. 10.1016/j.clml.2023.05.004
    By:
    • Sonneveld, Pieter;
    • Richardson, Paul G.;
    • Ludwig, Heinz;
    • Dimopoulos, Meletios-Athanasios;
    • Schjesvold, Fredrik H.;
    • Hajek, Roman;
    • Abdulhaq, Haifaa;
    • Thuresson, Marcus;
    • Norin, Stefan;
    • Bakker, Nicolaas A.;
    • Mateos, Maria-Victoria
    Publication type:
    Article
    34
    35

    P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S163, doi. 10.1016/S2152-2650(21)02351-X
    By:
    • Weisel, Katja;
    • Dimopoulos, Meletios-Athanasios;
    • Oriol, Albert;
    • Beksac, Meral;
    • Dimopoulos, Fredrik;
    • Liberati, Anna Marina;
    • Lindsay, Jindriska;
    • White, Darrell;
    • San-Miguel, Jesús F.;
    • Moreau, Philippe;
    • Anderson Jr., Larry D.;
    • Lorocca, Alessandra;
    • Robak, Pawef;
    • Vogel, Prisca;
    • Jiang, Ruiyun;
    • Grote, Lara;
    • Peluso, Teresa;
    • Richardson, Paul G.
    Publication type:
    Article
    36

    P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S156, doi. 10.1016/S2152-2650(21)02339-9
    By:
    • Richardson, Paul G.;
    • Trudel, Suzanne;
    • Callander, Natalie S.;
    • Nooka, Ajay;
    • Song, Kevin;
    • Uttervall, Katarina;
    • Minnema, Monique C.;
    • Rodríguez-Otero, Paula;
    • Struemper, Herbert;
    • Yeakey, Anne;
    • de Oca, Rocio Montes;
    • Smith, L. Mary;
    • Jackson, Nicola;
    • Kaisermann, Morrys;
    • Im, Ellie;
    • Basile, Frank G.;
    • Ahlers, Christoph M.;
    • Holkova, Beata;
    • Gupta, Ira;
    • Kremer, Brandon E.
    Publication type:
    Article
    37

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    38

    P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
    By:
    • Dimopoulos, Meletios-Athanasios;
    • Dytfeld, Dominik;
    • Grosicki, Sebastian;
    • Moreau, Philippe;
    • Takezako, Naoki;
    • Hori, Mitsuo;
    • Leleu, Xavier;
    • LeBlanc, Richard;
    • Suzuki, Kenshi;
    • Raab, Marc;
    • Richardson, Paul G.;
    • McKiver, Mihaela Popa;
    • Ying-Ming Jou;
    • David Yao;
    • Das, Prianka;
    • San-Miguel, Jesús F.
    Publication type:
    Article
    39

    P-150: Quality of life, psychological distress, and prognostic awareness in patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S117, doi. 10.1016/S2152-2650(21)02277-1
    By:
    • O'Donnell, Elizabeth;
    • Shapiro, Yael;
    • Nadeem, Omar;
    • Yee, Andrew J.;
    • Laubach, Jacob;
    • Branagan, Andrew;
    • Anderson, Kenneth;
    • Mo, Clifton;
    • Munshi, Nikhil C.;
    • Ghobrial, Irene;
    • Sperling, Adam;
    • Agyemang, Emerentia;
    • Burke, Jill;
    • Harrington, Cynthia;
    • Richardson, Paul G.;
    • Raje, Noopur;
    • El-Jawahri, Areej
    Publication type:
    Article
    40

    P-134: Quality of life, psychological distress, and prognostic awareness in caregivers of patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S108, doi. 10.1016/S2152-2650(21)02261-8
    By:
    • ODonnell, Elizabeth;
    • Shapiro, Yael;
    • Nadeem, Omar;
    • Yee, Andrew J.;
    • Laubach, Jacob;
    • Branagan, Andrew;
    • Anderson, Kenneth;
    • Mo, Clifton;
    • Munshi, Nikhil C.;
    • Ghobrial, Irene;
    • Sperling, Adam;
    • Agyemang, Emerentia;
    • Burke, Jill;
    • Harrington, Cynthia;
    • Richardson, Paul G.;
    • Raje, Noopur;
    • El-Jawahri, Areej
    Publication type:
    Article
    41
    42

    OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S29, doi. 10.1016/S2152-2650(21)02119-4
    By:
    • Branagan, Andrew;
    • Lei, Matthew;
    • Yee, Andrew J.;
    • O'Donnell, Elizabeth;
    • Castillo, Jorge J.;
    • Raje, Noopur;
    • Treon, Steven P.;
    • Flynn, Catherine;
    • Burke, Jill;
    • Harrington, Cynthia;
    • Agyemang, Emerentia;
    • Mo, Clifton;
    • Nadeem, Omar;
    • Richardson, Paul G.;
    • Maebius, Allison;
    • Onyewadume, Chukwuamaka;
    • Panaroni, Cristina;
    • Meid, Kirsten;
    • Bernstein, Zachary;
    • Lyons, Rebecca
    Publication type:
    Article
    43

    OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S21, doi. 10.1016/S2152-2650(21)02107-8
    By:
    • Gulla, Annamaria;
    • Morelli, Eugenio;
    • Samur, Mehmet K;
    • Botta, Cirino;
    • Johnstone, Megan;
    • Bianchi, Giada;
    • Fulciniti, Mariateresa;
    • Leona Yamamoto;
    • Prabhala, Rao;
    • Wen, Kenneth;
    • Richardson, Paul G.;
    • Yu-Tzu Tai;
    • Chauhan, Dharminder;
    • Teru Hideshima;
    • Munshi, Nikhil C.;
    • Anderson, Kenneth
    Publication type:
    Article
    44

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    45

    MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01948-0
    By:
    • Richardson, Paul G.;
    • Perrot, Aurore;
    • San-Miguel, Jesus;
    • Beksac, Meral;
    • Spicka, Ivan;
    • Leleu, Xavier;
    • Schjesvold, Fredrik;
    • Moreau, Philippe;
    • Dimopoulos, Meletios A.;
    • Huang, Jeffrey Shang-Yi;
    • Minarik, Jiri;
    • Cavo, Michele;
    • Prince, H Miles;
    • Cheng Zheng;
    • Dubin, Franck;
    • van De Velde, Helgi;
    • Anderson, Kenneth C.
    Publication type:
    Article
    46

    MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Blade, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    47
    48

    MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
    By:
    • Richardson, Paul G;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemi;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    49

    Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Bladé, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    50